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Summary
Incidence of rectal cancer in Croatia was 1174 cases in 2012. Most cases were diagnosed at an advanced stage, how-
ever there are a few diagnosed in cT1-2N0M0 stage which opens a window for transanal resection. These patients have to 
be staged meticulously not to disregard possible local spread of disease and nodal involvement. Endorectal ultrasound is 
not always easily available, therefore MRI is usually the method of choice for preoperative staging. Nevertheless, since the 
implementation of this mode of treatment advances in neoadjuvant and adjuvant therapy and multidisciplinary approach 
to treatment have blurred these clear cut indications. In this paper we discuss specificities in selection, treatment and follow 
up of these patients.
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TRANSANAL EKSCIZIJA ZA REKTALNI KARCINOM- MULTIDISCIPLINARNI PRISTUP?
Sa`etak
Incidencija karcinoma rektuma u Hrvatskoj je oko 1174 slu~ajeva u 2012 godini. Ve}ina slu~ajeva je dijagnosticirana u 
poodmaklim stadijima bolesti, ipak odre|en broj se dijagnosticira u cT1-T2N0M0 stadiju {to otvara mogu}nost za transanal-
nu eksciziju. Pacijenti kod kojih se predvi|a trananalna ekscizija moraju biti u potpunosti slikovno obra|ena kako se pre-
operativno ne bi previdjela pro{irenja bolest. Endorektalni ultrazvuk nije {iroko dostupan, tako da se naj~e{}e koristi MR pri 
odluci o vrsti zahvata. Unato~ dosta jasno definiranim indikacijama za ovaj zahvat, napredak u neoadjuvantom i adjuvant-
nom pristupu te multidisciplinarnosti lije~enja je iste relativizirao. U ovom preglednom radu raspravit }emo izbor, vrstu 
lije~enja i pra}enja ovih pacijenata.
KLJU^NE RIJE^I: transanalna resekcija, karcinom rektuma, transanalni ultrazvuk, MR, indikacije
INTRODUCTION
Incidence of rectal cancer in Croatia is 1174 
cases in 2012 (1). Sixty percent of these are diag-
nosed in stages III/IV which require multidisci-
plinary approach- treatment sequence based on 
preoperative staging. Transanal excision for rectal 
cancer are indicated in early-stage cancers in high-
ly selected patients. The lesions suitable for trans-
anal excision are small lesions (< 3 cm in size), oc-
cupying less than a third of a circumference of the 
rectum, preferably exophytic/polypoid, superfi-
cial and non fixed (T1 and T2 lesions), low-grade 
(well or moderately differentiated), non mucinous 
that are located within 8 cm of the anal verge with-
out radiological evidence of nodal involvement in 
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the abdomen and pelvis. The advantages of local 
excision include rapid recovery, minimal effect on 
sphincter function, and relatively low periopera-
tive morbidity and mortality. It can also eliminate 
defecation, sexual and urinary dysfunction, and 
can prevent the need for a permanent stoma. 
However, one should carefully select patients. 
Even when following these selection criteria, 3-
30% of patients may experience recurrence (2).
EVOLUTION OF THE APPROACH
In 1977, Morson published a paper with a se-
ries of 91 patients with complete transanal exci-
sion of rectal cancer achieving local recurrence of 
3% (3). However, later series did not keep up with 
low recurrence rates of radical surgery vs. trans-
anal resection 3-6% to 8,2-23% T1 and 13-30% and 
7,2% T2 (2). Nevertheless, local excision is increas-
ingly used to treat stage I rectal cancer despite its 
inferiority to total mesorectal excision, which is 
the current standard of care. In a study of all rectal 
cancer patients in the National Cancer Data Base 
from 1998 through 2010, researchers found that lo-
cal excision was used to treat 46.5% of those with 
T1 tumors and 16.8% of those with T2 tumors. For 
patients with T1 cancer, local excision rates in-
creased from 39.8% in 1998 to 62.0% in 2010. For 
patients with T2 cancers, rates increased from 
12.2% to 21.4% (4,5).
DIAGNOSIS AND LOCATION
According to American Society of Colon and 
Rectum Surgeons Practice Parameters guidelines 
for the treatment of rectal carcinoma, digital rectal 
exam and proctosigmoidoscopy should be per-
formed to establish the distance of the tumor from 
the anal verge, its mobility and position (6). Digi-
tal rectal examinations may characterize lesion as 
mobile, tethered or fixed. In fact, large and fixed 
tumors are not eligible for local excision as they 
often invade deeper layers (7). Colonoscopy 
should be performed prior to surgery to detect si-
multaneous polyps or tumors.
T1/T2 EVALUATION
Most important criteria for selecting patients 
for transanal excision is extent of rectal wall in-
volvement. Tis means that the process is in the 
earliest stage (in situ) when it involves only the 
mucosa- not growing beyond the muscularis mu-
cosa (thin inner muscle layer). T1 stage means that 
the cancer spread through the muscularis mucosa 
and extends into the submucosa. In T2 stage can-
cer has grown through the submucosa and ex-
tends into the muscularis propria (thick outer 
muscle layer).
Endoscopic rectal ultrasound (ERUS) is com-
parable to magnetic resonance (MR) in estimating 
the thickness of rectal wall tumor spread. Patel et 
al. compared T1/T2 sensitivity and specificity of 
ERUS and MR in 52 patients. Specificity of 100% 
of ERUS was similar to its sensitivity. Specificity 
of MRI was similar to that of ERUS (8). In another 
series, Zorcolo et al. achieved higher accuracy 
rates in distinguishing early from advanced rectal 
lesion with 96% sensitivity and 85% specificity, 
giving accuracy of 94% in 67 patients (9).
Lymphnode involvement
The exclusion criteria for transanal excision is 
nodal positivity. Assessment of nodal metastases 
by ERUS is less accurate than that for tumor depth. 
According to a meta-analysis of 35 studies by Puli 
et al, which involved more than 2700 patients, the 
sensitivity of ERUS in diagnosing nodal involve-
ment in rectal cancer was 73.2% and it had a spec-
ificity of 75.8% (10).
Turkish study compared the detection of 
lymph node metastases by MR and ERUS, obtain-
ing an accuracy of 74.50% with phased-array MRI 
and 76.47% with ERUS. Sensitivity was slightly 
better with MRI than ERUS (61.76% and 52.94% 
respectively) (11).
Estimates of lymph node involvement are also 
based on analysis of pathological specimens after 
radical excision. Saraste et al. stratified risk of 
lymph node involvement in early rectal cancer, 
identifying T2-stage (odds ratio [OR] = 2.0), poor 
differentiation (OR = 6.5) and vascular infiltration 
(OR = 4.3) as significant risk-factors for lymph node 
metastases in the multivariate analysis. The risk 
stratification index shows the risk for lymph node 
metastases gradually increasing from 6% to 65% 
and 11% to 78% in T1 and T2 cancers respectively, 
when adding these risk factors one by one (12).
According to the review by Maeda et al., the 
likelihood of lymph node involvement for T1 rang-
es from 6,3 to 20% and for T2 from 14 to 26% (13).
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TECHNIQUE
Transanal resection is suitable for lesions up 
to 8 cm from the anal verge. Local excision results 
in a full-thickness specimen including some meso-
rectal fat with at least 1 cm circumferential mucosal 
margins. The specimen is usually oriented and 
fixed on a board by the operator to preserve the ori-
entation and specimen contraction during patho-
histological sample preparation. The defect in the 
bowel wall is subsequently closed in a transverse 
manner. Patients perform a full mechanical bowel 
preparation prior to the surgery. Postoperative re-
covery is quick, with early start of regular diet and 
everyday activities and minimal discomfort (14).
Alternative procedure for local excision of 
rectal cancer is transanal endoscopic excision 
(TME) which requires more logistics (specialized 
instruments) than transanal excision. Due to tech-
nical requirements and learning curve TEM is not 
widely available, despite the fact that it is more 
precise than transanal excision. TEM remains the 
gold-standard for the resection of rectal adeno-
mas. TEM has a significantly decreased rate of R1 
resection compared to traditional transanal exci-
sion (2% vs. 16%) (15), but achieving an R0 resec-
tion did not prevent local recurrence (16). Even 
when stratifying to low-risk T1 tumors, there is 
still a 17% local recurrence rate after TEM (16). 
There was no significant difference in the 5-year 
recurrence rate between T1 and T2 tumors re-
moved by either of local excision techniques (21% 
vs. 33%, P=0.07) (15). Due to the high rate of local 
recurrence in low-risk patients with even an R0 
resection, improving criteria for tumor resection 
by TEM is of major importance.
OVERALL SURVIVAL 
AND RECURRENCE RATE
The 5-year survival rate after transanal exci-
sion ranges from 65-100% (these figures include 
some patients with T2 lesions). The local recur-
rence rate ranges from 0-40%. Patients with lesions 
that display unfavorable histologic features but 
are excised completely may be treated with adju-
vant chemo/radiation therapy. Cancer recurrence 
following transanal excision of early rectal cancer 
has been studied by Weiser et al., who observed 
that failures due to transanal excision are mostly 
due to understaging of local disease (17).
The main problem of transanal excision for 
early rectal cancer in a scandinavian study was 
also the inability to remove all the malignancy. Pa-
tients treated with transanal excision had signifi-
cantly higher rates of local recurrence and inferior 
survival compared with patients who underwent 
major surgery. The inferior survival in local exci-
sion group, could be because they were older than 
those who had major surgery (18). Chinese group 
published comparable results of major surgery 
and excision in elderly patients and transrectal ex-
cision, identifying a subpopulation in which this 
approach might be preferred (19).
SALVAGE SURGERY
In case of positive resection margins, lym-
phovascular or perineural invasion, lymph node 
metastasis or recurrent lesion at follow-up, sal-
vage resection is indicated. Usually, salvage resec-
tion is either abdominal perineal resection or TME 
with coloanal anastomosis (14). On one hand, 
LTME after TEM is a technically challenging pro-
cedure, with a higher risk of APR compared to 
primary LTME (20). On the other hand, the out-
come between patients with rectal cancer under-
going salvage TME after TEM, and those under-
going primary TME were comparable. In selected 
patients, TEM can therefore be chosen as a prima-
ry treatment, since failure of treatment and subse-
quent conventional resection appears not to com-
promise the outcome (21).
Borschitz et al. found that patients with high 
risk T1 tumors, <1 mm margins, tumor fragmenta-
tion, or R1 resection had 49 % 10-year survival as 
compared to 89 % among patients with low-risk 
tumors and R0 resection (22).
The discovery of adverse pathologic charac-
teristics after local excision should be followed by 
immediate radical resection, which may be per-
formed without adverse oncologic outcome com-
pared to primary radical resection. It needs to be 
stressed, even with intensive surveillance, delay-
ing TME until the clinical appearance of recur-
rence has been shown leads to significantly worse 
rates of survival and resectability (23).
FOLLOW UP
Heafner suggested the follow up scheme us-
ing CT/MRI with ERUS postoperatively to in-
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crease the sensitivity in detecting locoregional re-
currences. History and physical examination is 
performed every 3-6 months for the first 2 years 
and then annually after. Preoperative CEA is ob-
tained and on subsequent followup visits. Digital 
rectal exam and proctoscopy or flexible sigmoid-
oscopy are performed every 3-6 months for 2 years 
and then yearly after to detect recurrences, alter-
nated with ERUS every 6 months to evaluate for 
lymph nodes. Every year, CT or MRI are obtained 
for detecting local or distant recurrences. Most 
surveillance schedules only extend out to five 
years, but long-term follow-up after local excision 
should be pursued (2).
COMBINATION WITH NEOADJUVANT 
AND ADJUVANT TREATMENT
Neoadjuvant chemoradiation reduces local 
recurrence rates and downstages primary tumors 
in patients with rectal cancers (24,25). Tumor 
downstaging and downsizing has been demon-
strated in 51-64% and 26-100% of T2 rectal cancers, 
respectively (2). However, complete clinical re-
sponse only translates to a 30-60% pathologically 
complete response meaning there is minimal dis-
ease recurrence.
Lezoche et al. noted overall recurrences oc-
curred primarily in the low response and non-re-
sponder groups, at rates of 12% after local excision 
and 10% after radical resection (26). A more ag-
gressive surgical approach is indicated for these 
patients, as an incomplete response likewise may 
exist in the regional lymph nodes (27).
In the transanal excision of T2 rectal cancer, 
neoadjuvant therapy has shown favorable short-
term and similar long-term oncological outcomes 
to radical resection. One should not disregard the 
increased rate of post-operative complications due 
to neoadjuvant treatment (most are minor com-
plications (91%) solvable without additional sur-
gery (28).
The use of neoadjuvant therapy for T2 rectal 
cancer should be used with caution, since radical 
surgery alone provides an adequate treatment for 
T2 N0 disease. Possible role of neoadjuvant treat-
ment is to downsize and downstage borderline 
T2-T3 tumors. Local excision may then be utilized 
to determine the pathological response to the 
chemoradiation or as definite treatment. In case of 
partial response or remaining tumor tissue, imme-
diate radical resection should be performed (2).
CONCLUSION
Transanal excision for rectal cancer may be a 
definitive therapy for highly selected early rectal 
cancers, in combination with chemoradiotherapy 
for more advanced tumors, or as a palliative pro-
cedure for patients unable to undergo transab-
dominal operation. Development of novel tech-
niques such as transanal endoscopic microsurgery 
(TEM) did not significantly justify extending rath-
er narrow indications for this type of surgery. In 
fact, oncologic adequacy of local excision is dis-
cussed with caution. There is a lack of prospective, 
randomized trials and published series vary in 
terms of patient selection, adjuvant therapy, sur-
gical technique, and length of follow-up.
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